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Abstract: Here, we report a case of a middle-aged woman presenting with severe, long-standing, 
hyperkeratotic plaques of the lower extremities unrelieved by over-the-counter medications. 
Initial history and clinical findings were suggestive of an inherited ichthyosis. Ichthyoses are 
genetic disorders characterized by dry scaly skin and altered skin-barrier function. A diagnosis 
of ichthyosis vulgaris was confirmed by histopathology. Etiology, prevalence, and treatment 
options are discussed.
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Introduction
Inherited ichthyoses are a diverse group of genetic disorders characterized by dry, 
scaly skin; hyperkeratosis; and altered skin-barrier function. While these disorders of 
cutaneous keratinization are multifaceted and varying in etiology, disruption in the 
stratum corneum with generalized scaling is common to all.1–4 Although not entirely 
known how each diverse genetic process of the ichthyoses could lead to a similar 
phenotype, a weakened epidermal barrier allowing for inflammation and subsequent 
hyperproliferation of the skin is hypothesized.1–4
Various ichthyoses can be differentiated from one another through history,  clinical 
exam, histopathological analysis, electron microscopy, and genetics. Determining 
the inheritance pattern is an important part of the family history; this information is 
helpful in both formulating the differential diagnosis as well as in understanding the 
variable expressivity and severity of the disorder.1,3,4 It is also important to know: 
if the ichthyosis is congenital or was acquired later in adulthood; whether there is 
a presence or absence of erythroderma; and the features and specific appearance of 
the scale, as well as any other systemic manifestations of the disease.1,3,4 Although 
histopathological analysis can be useful to differentiate some of the ichthyoses, such 
as epidermolytic hyperkeratosis, other ichthyoses may not be able to be distinguished 
from one another via this manner alone.1,3,4
Ichthyosis vulgaris (IV), the most frequently occurring ichthyosis, is caused by 
mutations in the filaggrin gene (FLG).1,3–13 Typical hallmarks of IV, which  encompass 
a wide clinical spectrum, include visible scaling and dryness that spares flexural 
 surfaces, hyperlinearity of palms and soles, and strong predisposition for allergic 
disease comorbidities.1,3–11 Prevalence estimates for IV range from 4.0% to 7.7% in 
Europeans and 2.29% to 3.00% in Asians; observations of FLG mutations in darkly 
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A 57-year-old female with new-onset dyspnea was evaluated 
for severely hyperkeratotic skin of bilateral lower  extremities 
(Figures 1 and 2). The lesions were reported as beginning 
during childhood, initially on the feet and progressing 
 proximally to the level of the knee. The lesions, which were 
occasionally pruritic, had worsened over the prior 14 years 
and were not relieved by over-the-counter medications. 
 Family history was significant for several generations of 
males and females with similar appearing skin as well as 
many unaffected family members. Our patient indicated 
improvement in symptoms when living in warmer, more 
humid environments with worsening of symptoms while 
living at more northern latitudes.
Discussion
IV, a genetically transmitted, autosomal semi- dominant 
 disorder, exhibits varying penetrance of FLG muta-
tions.4,6,8,13–19 Individuals heterozygous for the FLG muta-
tion often have a less severe form of the disease than those 
homozygous for the mutation.4,7,8,10,14–19 FLG encodes for a 
protein called profilaggrin, which functions as a precursor 
to filaggrin (or filament-aggregating protein).7 Profilaggrin 
is stored in the granular layer of the epidermis as the major 
component of keratohyalin granules.3,4,7,15 Profilaggrin is 
cleaved into multiple filaggrin peptides that aggregate the 
keratin filaments. These keratin filament complexes are then 
cross-linked to the cell envelope and are important in main-
taining the compact layer of skin and serving as a natural 
moisturizer.3–5,6,8,16–19
It has long been established that IV is associated with 
a decreased and even absent number of keratohyalin 
granules due to the deficiency of filaggrin proteins.4,7,15 
A  compensatory epidermal hyperplasia with inflammation, 
abnormal desquamation, and hyperkeratosis results in an 
impaired  epidermal barrier, water loss, and dehydration.1,9,16,20 
 Chemicals and allergens are more prone to cross the impaired 
barrier, leading to sensitization and an increased propensity 
for inflammatory skin conditions.1,4,21–23
IV is usually not clinically present at birth and may 
have a variety of presentations later in life. With  inherited 
IV,  symptoms usually begin before age 1 year and alter-
nate between exacerbation and remission. With milder 
 presentations, patients present with flaky white scaling 
patches, often on extremities and extensor surfaces,  typically Figure 1 Hyperkeratotic skin of the lower extremity.
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Hyperkeratotic plaques of ichthyosis vulgaris
sparing the  flexural and more hydrated areas of the body.3,4,15 
More severe cases of IV are rare and may show an increased 
hyperkeratosis of the palmoplantar skin with f issures 
 forming on the heels of the feet.1,4,15 The flaking scales may 
be pronounced over the head, trunk, face, and extremities. 
Intertriginous areas of the body (armpits, groin, etc), are 
usually spared.1,4,15
Increased humidity explains the seasonal variation seen 
in IV. Symptoms often improve in the summer months and 
worsen in the cold and dry winter months, when the decreas-
ing humidity further breaks down the residual filaggrin left 
in the skin.1,4,15 IV is frequently associated with the atopic 
triad of atopic dermatitis, hay fever, and asthma as well as 
with keratosis pilaris.4–7,11,16,18,19 It is hypothesized that the 
epidermal barrier abnormality continually exposes the body 
to pathogens and allergens, ultimately resulting in a T-helper 
2 immunophenotype consistent with atopy.4
Histopathologically, IV demonstrates orthohyperkerato-
sis, diminished to absent stratum granulosum, and decreased 
or absent keratohyalin granules on electron microscopy.1,4 In 
patients heterozygous for the gene mutation, the  keratohyalin 
granules may be present but appear small.3 Decreased or 
absent filaggrin on immunohistochemistry is characteristic 
as well.1,4
A histopathological analysis was done from a 4 mm 
punch biopsy of the right lower leg of our patient.  Findings 
revealed orthohyperkeratosis with a markedly reduced 
stratum  granulosum, consistent with IV. Figure 3 shows the 
histopathology of the punch biopsy specimen.
In this case, the severity of the IV was hypothesized to 
be related to her obesity and chronic lymphedema. Obesity 
is associated with mild chronic inflammation as well as 
impaired lymphatic drainage due to tissue compression.24–27 
Lymphedema, the result of an inability of the lymphatic 
 vasculature to remove fluid and lipids, leads to their 
 accumulation in interstitial spaces.24–32 Recent reports also 
note fibrotic changes in the extracellular matrix of  adipose 
tissue decrease lymphatic clearance of inflammatory 
 macromolecules from interstitial spaces.26,27
While lymphedema begins as spongy swelling, the chronic 
recurring inflammation induces an infiltrate of  fibroblasts and 
keratinocytes thus transforming the epidermal layer  leading 
to its subsequent thickening.28–32 Over time, the limb with 
untreated lymphedema gains a brawny and  indurated texture 
and histopathologically reveals  hyperkeratosis and papilloma-
tosis.28–32 Lymphedema-induced hyperkeratosis superimposed 
on the epidermal thickening associated with IV likely played 
a role in the exaggerated presentation in this case.
Treatment of IV is similar to that of many of the other 
ichthyoses and is symptomatic, complex, and dynamic.9,20–23,33 
Primary treatments are topical moisturizers and medications 
designed to reduce scaling, support skin-barrier function, 
reduce water loss, and decrease symptoms. Lessening the 
scale, providing hydration, and moisturization can be accom-
plished with emollients, humectants, bathing immediately 
followed with moisturizers, keratolytic agents, and topical 
retinoids.20,21 Management of bacterial skin infections, most 
commonly staphylococcal or streptococcal in origin, is done 
with topical mupirocin or bacitracin.21,23 On the horizon, 
researchers are attempting to use genetic pharmacology to 
increase the body’s own production of normal filaggrin.4,15
For this patient, first-line treatment for IV was begun using 
topical 0.1% tretinoin and 40% urea cream. At follow-up, 
warm bath soaks prior to medication application was added 
to the regimen to enhance absorption. At the  present time, 
marked objective clinical improvement, as well as subjective 
patient satisfaction with treatment, is noted. She continues 
to be followed in the dermatology clinic.
Conclusion
Our patient presented with an extreme presentation of a 
common disease. Based upon the history, IV was considered. 
However, the severity of the clinical presentation of hyperk-
eratosis strongly suggested an alternative diagnosis. This case 
is a helpful reminder that IV is the most common inherited 
ichthyosis, and therefore should be a diagnostic consideration 
in even extreme and atypical presentations.
Acknowledgments
Special thanks to the Department of Dermatology at West 












































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical, Cosmetic and Investigational Dermatology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal
Clinical, Cosmetic and Investigational Dermatology is an interna-
tional, peer-reviewed, open access, online journal that focuses on 
the latest clinical and experimental research in all aspects of skin 
disease and cosmetic interventions. All areas of dermatology will 
be covered; contributions will be welcomed from all clinicians and 
basic science researchers globally. This journal is indexed on CAS. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.






for providing medical student opportunity for case study 
research. Manuscript editing assistance was provided by 
Susan B Leight, EdD, FNP-BC, FAANP, Director, School 
of Nursing, West Virginia Wesleyan College. The authors 
advise that the West Virginia University Ethics Committee/
Institutional Review Board does not require patient approval 
for case reports.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. Philadelphia, 
PA: Elsevier Saunders; 2012.
 2. Styperek AR, Rice ZP, Kamalpour L, et al. Annual direct and indirect 
health costs of the congenital ichthyoses. Pediatr Dermatol. 2010; 
27(4):325–335.
 3. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. 
Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York, NY: 
McGraw Hill; 2008.
 4. Thyssen JP, Godoy-Gijon E, Elias PM. Ichthyosis vulgaris: the filaggrin 
mutation disease. Br J Dermatol. 2013;168(6):1155–1166.
 5. Li M, Cheng R, Shi M, et al. Analyses of FLG mutation frequency 
and filaggrin expression in isolated ichthyosis vulgaris (IV) and atopic 
dermatitis-associated IV. Br J Dermatol. 2013;168(6):1335–1338.
 6. Wells RS, Kerr CB. Clinical features of autosomal dominant and sex-linked 
ichthyosis in an English population. BMJ. 1966;1(5493):947–950.
 7. Liu P, Yang Q, Wang X, et al. Identification of a genetic locus for 
ichthyosis vulgaris on chromosome 10q22.3-q24.2. J Invest Dermatol. 
2008;128(6):1418–1422.
 8. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al.  Comprehensive 
analysis of the gene encoding filaggrin uncovers prevalent and rare 
mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 
2007;39(5):650–654.
 9. Bellew S, Del Rosso JQ. Overcoming the Barrier Treatment of 
 Ichthyosis: A Combination-therapy Approach. J Clin Aesthetic  Dermatol. 
2010;3(7):49–53.
 10. Perusquίa-Ortiz AM, Oji V, Sauerland MC, et al. Complete filaggrin 
deficiency in ichthyosis vulgaris is associated with only moderate 
changes in epidermal permeability barrier function profile. J Eur Acad 
Dermatol Venereol. 2013;27(12):1552–1558.
 11. Dreyfus I, Bourrat E, Maruani A, et al. Factors associated with impaired 
quality of life in adult patients suffering from ichthyosis. Acta Derm 
Venereol. 2014;94(3):344–346.
 12. Dreyfus I, Pauwels C, Bourrat E, et al. Burden of inherited ichthyosis: 
a French national survey. Acta Derm Venereol. 2015;95(3):326–328.
 13. Esparza-Gordillo J, Matanovic A, Marenholz I, et al. Maternal filaggrin 
mutations increase the risk of atopic dermatitis in children: an effect 
independent of mutation inheritance. PLoS Genet. 2015;11(3):1–16.
 14. Mendes MS, Aquino TA, de Padua Lima A, Kouzak SS, Takano GH. 
Mosaic epidermolytic ichthyosis – case report. An Bras Dermatol. 
2013;88(6 Suppl 1):116–119
 15. Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest 
Dermatol. 2012;132(3 Pt 2):751–762.
 16. Akiyama M. FLG mutations in ichthyosis vulgaris and atopic eczema: 
spectrum of mutations and population genetics. Br J Dermatol. 2010; 
162(3):472–477.
 17. Zhang X, Liu S, Chen X, et al. Novel and recurrent mutations in 
the  filaggrin gene in Chinese patients with ichthyosis vulgaris. Br J 
 Dermatol. 2010;163(1):63–69.
 18. Nomura T, Akiyama M, Sandilands A, et al. Prevalent and rare muta-
tions in the gene encoding filaggrin in Japanese patients with ichthyo-
sis vulgaris and atopic dermatitis. J Invest Dermatol. 2009;129(5): 
1302–1305.
 19. Winge MCG, Hoppe T, Berne B, et al. Filaggrin genotype determines 
functional and molecular alterations in skin of patients with atopic 
dermatitis and ichthyosis vulgaris. PLoS One. 2011;6(12):e28254.
 20. Blanchet-Bardon C, Tadini G, Machado Matos M, Delarue A. 
 Association of glycerol and paraffin in the treatment of ichthyosis in 
children: an international, multicentric, randomized, controlled, double-
blind study. J Eur Acad Dermatol Venereol. 2012;26(8):1014–1019.
 21. Fleckman P, Newell BD, van Steensel MA, Yans, AC. Topical treatment 
of ichthyoses. Dermatol Ther. 2013;26(1):16–25.
 22. Bodemer C, Bourrat, E, Mazereeuw-Hautier J, et al. Short- and medium-
term efficacy of specific hydrotherapy in inherited ichthyosis. Br J 
Dermatol. 2011;165(5):1087–1094.
 23. Chan A, Godoy-Gijon E, Nuno-Gonzalez A. et al. Cellular basis of 
secondary infections and impaired desquamation in certain inherited 
ichthyoses. JAMA Dermatol. 2015;151(3):285–292.
 24. Divyashree RA, Naveen KN, Pai VV, Athanikar SB, Gupta G. Cutaneous 
manifestations of obesity among dermatology patients in a tertiary care 
center. Indian J Dermatol Venereol Leprol. 2014;80(3):278.
 25. Greene AK, Grant FD, Slavin SA. Lower-extremity lymphedema and 
elevated body-mass index. N Engl J Med. 2012;366(22):2136–2137.
 26. Weitman ES, Aschen SZ, Farias-Eisner, et al. Obesity impairs lymphatic 
fluid transport and dendritic cell migration to lymph nodes. PLoS One. 
2013;8(8):e70703.
 27. Arngrim N, Simonsen L, Holst JJ, Bülow J. Reduced adipose tissue 
lymphatic drainage of macromolecules in obese subjects: a possible 
link between obesity and local tissue inflammation? Int J Obes (Lond). 
2013;37(5):748–750.
 28. Scheinfeld, NS. Obesity and dermatology. Clin Dermatol. 2004; 
22(4):303–309.
 29. Boza JC, Trindade EN, Peruzzo J, Sachett L, Rech L, Cestari TF. Skin 
manifestations of obesity: a comparative study. J Eur Acad Dermatol 
Venereol. 2012;26(10):1220–1223.
 30. Lu S, Tran TA, Jones DM, et al. Localized lymphedema (elephantiasis): 
a case series and review of the literature. J Cutan Pathol. 2009;36(4): 
1–20.
 31. Kaba H, Bakar Y, Ozdemir Oç, Sertel S. Complex Decongestive 
Physiotherapy Treats Skin Changes like Hyperkeratosis Caused by 
Lymphedema. Case Rep Dermatol Med. 2012;2012:416421.
 32. Linnitt N. Complex skin changes in chronic oedemas. Br J Community 
Nurs. 2007;12(4):S10–S15.













































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
